The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1407
ISSUE 1407
January 7, 2013
Issue 1407
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Tofacitinib (Xeljanz) for Rheumatoid Arthritis
January 7, 2013 (Issue: 1407)
The FDA has approved tofacitinib (toe” fa sye’ ti nib;
Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for
treatment of adults with moderately to severely active
rheumatoid arthritis (RA) who have had an inadequate
response to or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.